trial · primary record
Azacitidine
FLT3 Gene Mutation Negative
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 73 |
| Primary completion | 2023-02-07 |
| Primary endpoint | Maximum Tolerated Dose of Quizartinib (Phase I) |
| Registry ID | NCT01892371 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:58.302Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT01892371
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.